Arcede Pharma and Iconovo take the next step in the development of a new treatment for COPD
Arcede Pharma, which develops inhalation treatments for COPD and severe asthma, and Iconovo AB (publ), which develops complete inhalation products for a global market, announce today that the collaborative project around Arcede's drug candidate RCD405 is progressing with good results. The next step in the project is a technical stability study before the drug candidate can be tested clinically.The project supported by SweLife is part of the previously communicated collaboration between Arcede Pharma, Iconovo and Lund University for the development of the drug candidate RCD405 primarily for